Effect of rivastigmine on regional cerebral blood flow in Alzheimer's disease

Basit Öğe Kaydı
dc.contributor.authorCerci, Sevim Sureyya
dc.contributor.authorTamam, Yusuf
dc.contributor.authorKaya, Halil
dc.contributor.authorYildiz, Mustafa
dc.contributor.authorArslan, Seyfi
dc.date.accessioned2024-04-24T15:59:39Z
dc.date.available2024-04-24T15:59:39Z
dc.date.issued2007
dc.departmentDicle Üniversitesien_US
dc.description.abstractCholinesterase inhibitors improve or stabilize cognitive impairment in patients with Alzheimer's disease (AD). The purpose of this study was to detect brain perfusion changes and the effects of rivastigmine, an acetylcholinesterase inhibitor on single photon emission computed tomography (SPECT) before and after treatment. Fifteen patients who fulfilled the clinical criteria for probable AD of mild to moderate severity, as put forth by the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association, and as specified by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, were included in the study. A control group of 15 healthy individuals from the same age and education range was included in the study. Before treatment was begun, Mini Mental State Examination (MMSE) tests were performed on all patients to evaluate cognitive function. All patients underwent baseline SPECT for evaluation of 25 different brain regions. Rivastigmine 3 mg/d was given for the first 4 wk of treatment; the dosage was then increased to 6 mg/d. The MMSE and SPECT were repeated 6 mo after the start of treatment. SPECT findings revealed that rivastigmine did not significantly affect brain perfusion in AD cases except in the inferior frontal lobe, despite stabilization and improvement noted in MMSE scores during treatment. Rivastigmine treatment of patients with AD did not significantly change brain perfusion as seen on SPECT, except in the inferior frontal lobe, but cognitive performance was stabilized or improved during the treatment course. These findings suggest the need for additional, larger studies to investigate the effects of acetylcholinesterase inhibitors on regional cerebral blood flow.en_US
dc.identifier.doi10.1007/BF02848786
dc.identifier.endpage621en_US
dc.identifier.issn0741-238X
dc.identifier.issn1865-8652
dc.identifier.issue3en_US
dc.identifier.pmid17660172
dc.identifier.scopus2-s2.0-34548063486
dc.identifier.scopusqualityQ1
dc.identifier.startpage611en_US
dc.identifier.urihttps://doi.org/10.1007/BF02848786
dc.identifier.urihttps://hdl.handle.net/11468/14190
dc.identifier.volume24en_US
dc.identifier.wosWOS:000248672300019
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofAdvances in Therapy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAlzheimer's Diseaseen_US
dc.subjectRivastigmineen_US
dc.subjectBrain Specten_US
dc.subjectRcbfen_US
dc.subjectMmseen_US
dc.titleEffect of rivastigmine on regional cerebral blood flow in Alzheimer's diseaseen_US
dc.titleEffect of rivastigmine on regional cerebral blood flow in Alzheimer's disease
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu